Shares of Cara Therapeutics (NASDAQ:CARA) decreased in after-market trading after the company reported Q2 results.

Quarterly Results

Earnings per share decreased 12.96% year over year to ($0.61), which missed the estimate of ($0.53).

Revenue of $0 decreased by 100.00% year over year, which missed the estimate of $2,360,000.

Guidance

Cara Therapeutics hasn't issued any earnings guidance for the time being.

Cara Therapeutics hasn't issued any revenue guidance for the time being.

Conference Call Details

Date: Aug 09, 2021

Time: 04:30 PM

ET Webcast URL: https://edge.media-server.com/mmc/p/pwxsdk9t

Price Action

Company's 52-week high was at $29.65

52-week low: $11.22

Price action over last quarter: down 5.84%

Company Description